Frontlight ResearchEarly access
Metastatic breast cancer trials in United Kingdom
36 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Brighton, Cardiff, Guildford, London, Taunton
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Leeds, Rickmansworth
- Age
- 18 years and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- London
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 3Taking peopleElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Edinburgh, London, Oxford, Surrey Quays, Truro, Waterlooville
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseActive, not recruitingAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Birmingham, Bristol, Cardiff, Dundee, Edinburgh, Glasgow, Manchester, Nottingham, Swansea, Truro, Yeovil
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - No phaseTaking peopleHER2+ CNS Surveillance
- Where
- Liverpool
- Age
- 16 years and over
- People
- 69
- Run by
- The Clatterbridge Cancer Centre NHS Foundation Trust
See details and how to joinNCT07748598 - Phase 2Taking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Bath, Lancaster, London
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - Phase 1/2Taking peoplePhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Where
- Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 95 worldwide
- Run by
- Ellipses Pharma
See details and how to joinNCT05573126 - Phase 2Taking peopleInvestigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
- Where
- London
- Age
- 18 years to 64 years
- People
- 140 worldwide
- Run by
- Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00 - No phaseTaking peopleFeasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
- Where
- London
- Age
- 18 years and over
- People
- 200
- Run by
- Royal Marsden NHS Foundation Trust
See details and how to joinNCT07084571 - Phase 1/2Taking peoplePhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
- Where
- Newcastle upon Tyne
- Age
- 18 years and over
- People
- 43 worldwide
- Run by
- One-carbon Therapeutics AB
See details and how to joinNCT07151040 · EU 2024-519639-40-00